Friday Satellite Symposia

ACHIEVING INNOVATION IN CLL CARE: Evidence-Informed Choices With Targeted Options and Next Steps in Disease Management

This program is supported by independent educational grants from AbbVie, AstraZeneca, BeiGene, Ltd., and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

11:00 a.m. - 2:00 p.m. Eastern time
Omni Hotel at CNN Center
Grand Ballroom E- North Tower M4

Continuous or fixed-duration therapy with targeted agents (including BTK, PI3K, and BCL-2 inhibitors) in chronic lymphocytic leukemia (CLL) has overturned the decades-long consensus centered on immunochemotherapy and decisively become the new standard of care. When developing optimized regimens for patients, clinicians can now personalize treatment choices by selecting among targeted strategies or within potent drug classes. Future novel combinatorial approaches in CLL are also likely to usher in an era of potent, effective strategies with the ability to induce deeper and more durable responses.

In collaboration with the CLL Society, this CME-certified live Seminars and Tumor Board event will feature a panel of leading CLL experts who, mimicking the collaborative nature of real-world tumor boards, will blend serial, case-based discussion with mini seminars designed to illustrate how fully integrating targeted therapeutics—including BTK, PI3K, and BCL-2 inhibitors, as well as novel antibodies—can improve care across the clinical spectrum of CLL. Panelists will cover important clinical topics such as the personalized, evidence-based selection of upfront treatment strategies, therapeutic sequencing in progressive disease settings, safety management and distinctions among agent classes, and next-generation and novel combinatorial strategies. Throughout, the experts will profile tools and resources from the CLL Society that can be used to enhance patient care. Register today for this exciting event!

Chair:

John Gribben , MD, DSc, FRCP, FRCPath, FMedSci
Barts Cancer Institute, Barts and The London School of Medicine, Queen Mary, University of London
London,  United Kingdom

Speakers:

Farrukh T. Awan , MD
UT Southwestern Medical Center
Dallas,  TX

Thomas J. Kipps , MD, PhD
Moores Cancer Center, University of California, San Diego
La Jolla,  CA

Nicole Lamanna , MD
Columbia University Medical Center, New York-Presbyterian/Columbia University Medical Center
New York,  NY

Margaret Walker , PVI, PeerView Institute for Medical Education
Email: margaret.walker@peerview.com

Registration for In-Person Program
Registration for Virtual Program

Adapting Clinical Practice to a Rapidly Changing Therapeutic Landscape in Multiple Myeloma

This program is supported by educational grants from Bristol-Myers Squibb, Genentech, a member of the Roche Group, GlaxoSmithKline, Janssen Biotech, Inc. administered by Janssen Scientific Affairs, LLC, Karyopharm Therapeutics, Oncopeptides and Sanofi Genzyme.

11:00 a.m. - 2:00 p.m. Eastern time
Atlanta Marriott Marquis
Marquis Ballroom BCD

Attendees of the annual International Myeloma Foundation/Clinical Care Options cosponsored symposium will be able to interact with a panel of international experts as they discuss the evolving therapeutic advances for patients with multiple myeloma (MM) and how they are integrating these approaches in their own clinical practice.

Brian G.M. Durie, MD; Thomas G. Martin, MD; Philippe Moreau, MD; S. Vincent Rajkumar, MD; and Jesús F. San-Miguel, MD, PhD, will debate current clinical questions, discuss available evidence and challenges that affect therapeutic decisions, and highlight emerging treatment options for patients with MM. They will share their individual treatment recommendations for a series of patient cases while attendees vote on these case scenarios and compare their answers with the experts’. Attendees will also be able to text questions directly to the panel for discussion throughout the symposium.

Topics will include:

• Evidence for Treating High-Risk Smoldering MM
• Current Therapeutic Strategies for Newly Diagnosed MM
• Tailoring Management for Patients With MM in First Relapse
• Expert Guidance for Treatment After Multiple Relapses
• Evolving Role for BCMA-Targeted Therapies
• Future Directions in MM Care: Emerging Agents and Spotlight of Key Abstracts From ASH 2021
• Program Summary and Introduction to the 2022 MM Care Algorithm

Chair:

Brian G.M. Durie , MD
Cedars-Sinai Outpatient Cancer Center
Los Angeles,  CA

Speakers:

Thomas Martin , MD, PhD
University of California
San Francisco,  CA

Philippe Moreau , MD
University Hospital Hôtel-Dieu
Nantes,  France

S. Vincent Rajkumar , MD
Mayo Clinic
Rochester,  MN

Jesus San-Miguel
Clínica Universidad De Navarra
Pamplona,  Spain

Clinical Care Options , Meetings Department
Email: meetings@clinicaloptions.com

Registration for In-Person Program

Advances in CAR-T Cell Therapy Across Hematologic Malignancies: From Pipeline to Clinical Practice

This program is supported by an educational grant from Bristol-Myers Squibb. Provided by Clinical Care Options, LLC.

11:00 a.m. - 2:00 p.m. Eastern time
Atlanta Marriott Marquis
Atrium A

CAR T-cell therapy is at forefront of advances in the treatment of relapsed or chemotherapy-refractory leukemia, lymphoma, and myeloma. In this symposium, experts in these malignancies will use a case-based approach to examine current and emerging applications for CAR T-cell therapy, discussing key clinical data and providing their expert insights to maximize efficacy while appropriately managing toxicity. Throughout the symposium, attendees will interact with the experts using text-friendly audience response technology and will be introduced to proprietary interactive clinical tools for adverse event management. After each presentation, faculty will pause for a panel discussion and to answer questions from the audience. Discussion topics include:

• CAR T-cell therapy in lymphomas
• CAR T-cell therapy for myeloma
• CAR T-cell therapies for R/R (R/R) acute lymphoblastic leukemia (ALL)
• Effectively identifying and managing unique CAR T-cell–mediated adverse events

Chair:

Michael R. Bishop , MD
University of Chicago
Chicago,  IL

Speakers:

Jesús G. Berdeja
Sarah Cannon Research Institute
Nashville,  TN

Jae H Park , MD
Memorial Sloan Kettering Cancer Center
New York,  NY

Clinical Care Options , Meetings Department
Email: meetings@clinicaloptions.com

Registration for In-Person Program

Advances in Immune Thrombocytopenia: Expert Guidance to Navigate an Evolving Therapeutic Landscape

This program is supported by educational grants from Amgen, Dova Pharmaceuticals, Inc., and Sanofi Genzyme. Provided by Clinical Care Options, LLC.

11:00 a.m. - 2:00 p.m. Eastern time
Atlanta Marriott Marquis
Atrium B

New science has driven innovative medical practice in the recognition and management of immune thrombocytopenia (ITP). This symposium, focused on new advances and the latest research progress in ITP, will be balanced by practical expert guidance on current therapeutic strategies for initial and second-line treatment. The symposium agenda will include didactic data presentations by experts with case challenges, moderated panel discussion, and audience interactivity with ample time for questions and answers. Along with the experts, audience learners will explore key clinical questions, available evidence, and challenges that affect therapeutic decisions as well as receive personal expert treatment recommendations for each case. Throughout the symposium, learners will be able to vote on case scenarios and text questions to the panel for their consideration. Discussion topics will include:

• Initial Management of ITP: Diagnosis and Treatment Considerations
• Clinical Application of New Advances in the Management of Refractory ITP
• Caring for Special Populations of Patients With ITP/Thrombocytopenia
• 2022 Clinical Algorithm for the Management of ITP

Chair:

Keith R. McCrae , MD
Cleveland Clinic
Cleveland,  OH

Speakers:

Nichola Cooper , MD
Hammersmith Hospital, Imperial College London
London,  United Kingdom

Rachael F. Grace , MD
Children's Hospital Boston
Boston,  MA

Clinical Care Options , Meetings Department
Email: meetings@clinicaloptions.com

Registration for In-Person Program

Advances in the Therapeutic Management of Patients with Chronic Hematological Conditions- A Whiteboard Preceptorship

This program is supported by Novo Nordisk

11:00 a.m. - 2:00 p.m. Eastern time
Georgia World Congress Center
Thomas Murphy Ballroom 1-2, Level 5

An innovative and engaging whiteboard symposium at the 2021 ASH Annual Meeting. The activity will have two faculty speakers and consist of 1.5 hours of content. The faculty will include 2 national experts and the program design will allow for a high level of interactivity as there will be breaks in the faculty presentations where the learners experience whiteboard animations. There will also be interactive, case-based Q&A that the faculty will discuss with the audience. Learners will have access to downloadable whiteboard animations to support continuous learning and to share with colleagues and patients.

Speakers:

Robert E. Molokie , MD
Jesse Brown VA Medical Center
Chicago,  IL

Robert F. Sidonio Jr. , MD, MSc
Pediatric Hematologist/Oncologist, Medical Director of Hemophilia, Aflac Cancer & Blood Disorders Center Children’s Healthcare of Atlanta Associate Professor of Pediatrics, Emory University School of Medicine
Atlanta,  GA

Martin H. Steinberg , MD
Professor of Medicine, Boston University School of Medicine
Boston,  MA

John Guerriero , Med Learning Group
Email: john.guerriero@medlearninggroup.com

Aware of the Rare: The New Dawn! Updates in Diagnosing and Managing Rare Hematologic Disorders

This program is supported by Blueprint Medicines, Novartis Oncology, Rigel Pharmaceuticals, Inc.

11:00 a.m. - 2:00 p.m. Eastern time
Omni Hotel at CNN Center
Grand Ballroom A-C, M4/Grand Ballroom Level

During this symposium, participants will be presented with case-based scenarios on rare hematologic disorders that challenge them to make decisions that lead to optimal outcomes. Using an interactive, gaming approach, participants will have the opportunity to continually and actively engage with symposium content. The format is designed to closely replicate the real-life physician’s experience of treating patients with rare hematologic disorders. As such, with expert faculty input, the following topics may be discussed in relation to hematologic disorders:

• Pathophysiology of disease
• Establishing a diagnosis and recognizing differential diagnoses
• Traditional approaches to treatment, including mechanisms of action (MOAs), strengths, and limitations
• Key clinical trial data for newer (current and emerging) treatments: MOA, efficacy, safety, strengths, limitations, real-world data
• Key considerations in treatment selection – How do we personalize care?
• Strategies for improving overall patient care
• Collaborating with the multidisciplinary team

Chair:

Andrew Provan
Barts and The London School of Medicine and Dentistry
London,  United Kingdom

Speakers:

Daniel J. DeAngelo , MD, PhD
Dana-Farber Cancer Institute
Boston,  MA

Morag Griffin , MD
Department of Haematology, Leeds Teaching Hospitals NHS Trust
Leeds,  United Kingdom

Alexander Roeth , MD
Essen University Hospital
Essen,  Germany

Kristen Holt Holt Gresham , Medscape
Email: kholt@webmd.net

Registration for In-Person Program
Registration for Virtual Program

Cases and Conversations™: Modifying the Course of Sickle Cell Disease with Modern Interventions

This program is supported by Global Blood Therapeutics, Inc.

11:00 a.m. - 2:00 p.m. Eastern time
Hyatt Regency Atlanta
Centennial 2

This symposium will be held in PER’s Cases and Conversations format. The program will begin with conversations between the panelists discussing the burden of sickle cell disease, approaches to sickle cell disease treatment, complications associated with SCD and practical strategies for optimal management. This will be followed by a series of case studies that highlight key clinical concepts discussed in the prior segments.

Chair:

Kenneth I. Ataga , MD
UTHSC Center for Sickle Cell Disease
Memphis,  TN

Speakers:

Victor R. Gordeuk , MD
University of Illinois at Chicago
Carol Stream,  IL

Abdullah Kutlar , MD
Augusta University
Augusta,  GA

Ifeyinwa Osunkwo , MD, MPH
Atrium Health
Charlotte,  NC

Phil Talamo , Physicians' Education Resource, LLC (PER)
Email: ptalamo@gotoper.com

Diagnosis and Treatment of MF and PV: Where Are We and Where Are We Going?

This program is supported by Physicians' Education Resource, LLC (PER)

11:00 a.m. - 2:00 p.m. Eastern time
Hyatt Regency Atlanta
Centennial 1

This live program is designed to update physicians on the issues important to the diagnosis and risk stratification of MPNs, as well as novel and emerging treatment options for the management of PV and MF across lines of care. In addition, this program will offer physicians strategies for monitoring treatment response and making appropriate therapeutic choices across the disease course considering safety and patient-specific factors as part of the decision-making process. Future directions in the field will also be addressed and considered regarding how recent developments and highly anticipated trials may shape care in the future. To evolve the educational event to meet the diverse needs of our learners, PER is proposing incorporating the community expert perspective, as well as the voice of advance practice professionals (APPs).

The symposium is designed to educate audiences in an innovative, engaging format and will include a mix of didactic lecture, case-studies, panel discussions, and Q&A. Case-studies and panel discussions will be used by the Chair to challenge faculty on their treatment decisions and to give the opportunity for the audience to reflect on best practices and their own clinical decisions for higher educational engagement.

Chair:

Srdan Verstovsek , MD, PhD
M.D. Anderson Cancer Center
Houston,  TX

Speakers:

Andrew T. Kuykendall , MD
H. Lee Moffitt Cancer Center & Research Institute
Tampa,  FL

Lindsey Lyle , MS, PA-C
University of Colorado
Aurora,  CO

Laura C. Michaelis , MD
The Medical College of Wisconsin Inc.
Milwaukee,  WI

Abdulraheem Yacoub , MD
University of Kansas Cancer Center
Westwood,  KS

Phil Talamo , Physicians' Education Resource, LLC (PER)
Email: ptalamo@gotoper.com

Elucidating Novel BTKi Strategies in CLL/SLL and MCL: A Virtual Exploration to Bring Therapeutic Rationales and Evidence into Perspective

This program is supported by Lilly

11:00 a.m. - 2:00 p.m. Eastern time
Hyatt Regency Atlanta
Centennial 3

The live activity will feature a series of didactic presentations coupled with case presentations from prominent experts in the field that will be used as a starting point to discuss the latest data across CLL/SLL and MCL.

• The activity is designed to highlight and test participants on the most clinically relevant data in CLL/SLL and MCL, provide expert guidance on the interpretation of core concepts, and forecast the clinical impact of recent data sets.
• To enrich discussion and illuminate understanding of the evolution of BTK inhibition in liquid tumors, the program will feature a 2-3 minute video-based virtual exploration of the rationale and mechanism of action for BTK inhibitors in lymphoid malignancies. The video will be narrated by a faculty presenter and will be subsequently housed with the enduring activities.
• The faculty panel will convene to share their own practice preferences and perspectives on the clinical trial data and share clinical pearls from their own practices.
• To further enhance the integration of recent data into practice, the program will feature an interactive question-and-answer session with faculty throughout the activity to emphasize areas of educational need, highlighting areas of debate, and illustrating the application of new data in defined clinical situations.

Chair:

William G. Wierda , MD, PhD
MD Anderson
Houston,  TX

Speakers:

Peter Martin , FRCPC, MD, MS
Weill Cornell Medical College-New York Presbyterian Hospital
New York,  NY

Stephen J. Schuster , MD
Lymphoma Program, Abramson Cancer Center, University of Pennsylvania
Philadelphia,  PA

Michael Wang , MD
U.T. M.D. Anderson Cancer Center
Houston,  TX

Phil Talamo , Physicians' Education Resource, LLC (PER)
Email: ptalamo@gotoper.com

Experts Debate Treatment Decisions in Relapsed/Refractory Multiple Myeloma

This program is supported by Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Legend Biotech, Oncopeptides, Inc., and Sanofi Genzyme

11:00 a.m. - 2:00 p.m. Eastern time
Georgia World Congress Center
Georgia Ballroom 2, Level 3

The educational symposium will involve 4 faculty experts actively engaged in the care of patients with relapsed/refractory multiple myeloma. The satellite symposium will utilize an engaging, debate-style format in which expert faculty will cross-examine recent advances and current controversies in the treatment of relapsed/refractory multiple myeloma. The symposium will include polling questions, case-based discussions, short didactic sessions, and a Q&A, which will allow faculty to address participants’ most pressing clinical concerns. At the end of the symposium, faculty will highlight and reinforce the most important take-home messages for learners.

Chair:

Sagar Lonial , MD, FACP
Emory University - Winship Cancer Institute
Atlanta,  GA

Speakers:

Ajai Chari , MD
Mount Sinai School of Medicine
New York,  NY

Suzanne Lentzsch , MD, PhD
Columbia University Medical Center
New York,  NY

Jeffrey L. Wolf , MD
University of California San Francisco
San Francisco,  CA

Jennifer Bechan , Bio Ascend LLC
Email: bechan@bioascend.com

Registration for In-Person Program

Gene Therapy and Hemophilia Care Updates: Bringing Your Treatment Center Up to Speed

This program is supported by Pfizer and Spark Therapeutics

11:00 a.m. - 2:00 p.m. Eastern time
Omni Hotel at CNN Center
Grand Ballroom D1/D2

Advances in treatment have transformed hemophilia from a devastating and debilitating disease to one that can be managed. Despite these advances, many patients continue to face the burden of treatment and suffer morbidity from their disease. Gene therapy is uniquely positioned to potentially revolutionize the care of patients with hemophilia. Our expert panel will guide us in an interactive discussion on the advancements of gene therapy in hemophilia, including updates on clinical trials in hemophilia A and B, and will suggest strategies to help prepare for the implementation of gene therapy in hemophilia treatment centers.

Chair:

David Lillicrap , MD
Queen's University Richardson Laboratory
Kingston,  ON, Canada

Speakers:

Kollet Koulianos , MBA
National Hemophilia Foundation
New York,  DC

Susan U. Lattimore , RN, GCPH
Oregon Health & Science University
Portland,  OR

Andrew D Leavitt , MD
UCSF
San Francisco,  CA

Kristen Holt Gresham , Medscape
Email: kholt@webmd.net

Registration for In-Person Program
Registration for Virtual Program

Overcoming Barriers to Equitable Care for Patients with Multiple Myeloma

This program is supported by AbbVie, Inc ; Bristol-Myers Squibb

11:00 a.m. - 2:00 p.m. Eastern time
Georgia World Congress Center
Thomas Murphy Ballroom 3-4, Level 5

The faculty panel will engage in extensive discussion around opportunities to improve care delivery, including engaging patients to be active members of their care team through shared decision making; supporting enrollment in MM clinical trials, when appropriate; and solving practical challenges related to health literacy, medication adherence, and other barriers to optimal patient outcomes. the faculty panel will utilize evidence slides featuring (a) real-world data on MM practice patterns, challenges, and action plans from phase 1 and 2 of the IS-IME initiative in system- and community-based oncology practices, respectively; (b) latest evidence and guidelines for relapsed/refractory MM; and (c) expert consensus strategies to engage patients with MM in SDM.

Chair:

Joseph Mikhael , MD,FRCPC,MEd
Mayo Clinic Arizona
Scottsdale,  AZ

Speakers:

Sikander Ailawadhi , MD
Mayo Clinic
Jacksonville,  FL

Craig E. Cole , MD
Michigan State University
Lansing,  MI

Tamara Gonzalez , PRIME Education LLC
Email: t.gonzalez@primeinc.org

Registration for In-Person Program

Practice Changing Evidence to Personalize Immune Thrombocytopenia Care: How the Experts Handle Cases in Today’s Environment

This program is supported by Amgen, Inc

11:00 a.m. - 2:00 p.m. Eastern time
VIRTUAL PROGRAM

During this case-based symposium, clinical scenarios will be presented following key didactic presentations on clinically relevant information such as active understanding the disease state, challenges in treating ITP, and clinical trials. Faculty will be present onstage throughout the program for a structured discussion of key decision points for patients with ITP. With the understanding that there may be more than one appropriate treatment selection at each decision point, faculty will be challenged to substantiate each of their treatment choices with the most appropriate evidence that supports the options they choose. Participants will have the opportunity to reflect on how experts in the management of ITP, leverage key data sets to support decision making on when to initiate therapy, monitoring, and therapeutic switching. Audience participation will be integrated throughout the program to encourage interaction with faculty and engagement with the content, including the opportunity to see how their treatment decisions compare with the experts’ therapeutic choices.

Chair:

Nichola Cooper , MD
Hammersmith Hospital
London,  United Kingdom

Speaker:

Ivy Altomare , MD
Duke University Medical Center
Durham,  NC

Dayna Kleinstein , Physicians' Education Resource® (PER®)
Email: dkleinstein@gotoper.com

WHAT CLINICIANS WANT TO KNOW: Addressing Current Questions and Controversies in the Management of Hodgkin and Non-Hodgkin Lymphoma (Part 2 of a 4-part CME/MOC-accredited Symposia Series)

This program is supported by Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Incyte Corporation, Kite, A Gilead Company, Lilly, Seagen Inc

11:00 a.m. - 2:00 p.m. Eastern time
Omni Hotel at CNN Center
International Ballroom E-F, M2/International Ballroom Level

This CME/MOC program, part 2 of a 4-part series, will focus on the management of patients with Hodgkin and non-Hodgkin lymphoma. Five investigators will serve as faculty, one of whom will moderate the event. Prior to the program, Research To Practice (RTP) will recruit 5 general medical oncologists and hematologists to help frame the program’s content and agenda. RTP will work with these individuals to identify challenging clinical situations or questions from their practice for which they would seek input from an investigator. These clinicians will then participate in a Working Group session during which their questions will be presented. The session will be video-recorded and RTP will select excerpts for presentation during the live meeting. The symposium agenda will be divided into 5 modules, each featuring the presentation and discussion of select video excerpts from the Working Group and a faculty member-led presentation formally reviewing emerging research relevant to the issues and scenarios presented. To make the event even more relevant, attendees will use iPads to participate in a survey related to the topics, questions and cases discussed. Polling results will be interspersed throughout each module to foster additional debate. The program will also be simulcast for virtual attendees.

Chair:

Ann S. LaCasce , MD, MMSc
Dana-Farber Cancer Institute
Boston,  MA

Speakers:

Jeremy S. Abramson , MD
Massachusetts General Hospital Cancer Center
Boston,  MA

Martin H. Dreyling , MD, PhD
University Hospital
Munich,  DEU

Loretta Nastoupil , MD
The University of Texas MD Anderson Cancer Center
Houston,  TX

Gilles Salles , MD, PhD
Memorial Sloan Kettering Cancer Center
New York,  NY

Sylvia Eriksen , Research To Practice
Email: meetings@researchtopractice.com

Registration for In-Person Program
Registration for Virtual Program

New Targets, New Combinations, New Treatment Goals: Assessing Therapeutic Options to Personalize Care in Multiple Myeloma

This program is supported by Sanofi Genzyme, Takeda Oncology, Karyopharm Therapeutics, Oncopeptides

3:00 p.m. - 6:00 p.m. Eastern time
Hyatt Regency Atlanta
Centennial 3

This live program is designed to update physicians on the latest advancements in the clinical management of relapsed/refractory multiple myeloma, including novel agents under investigation, recently approved agents, and new combination approaches to treat this disease. In addition, this program will use case studies to apply recent findings to real-world case scenarios and will allow participants to reflect on how they might handle each scenario. The program is designed to be fast-paced and highly interactive between faculty and audience. Case-studies and panel discussions will be used by the Chair to challenge faculty on their treatment decisions and to give the opportunity for the audience to reflect on best practices and their own clinical decisions for higher educational engagement.

Chair:

Ajai Chari , MD
Mt. Sinai School of Medicine
New York,  NY

Speaker:

Nina Shah , MD
University of California San Francisco
San Francisco,  CA

Dayna Kleinstein , Physicians' Education Resource® (PER®)
Email: dkleinstein@gotoper.com

A Review of Current and Emerging Treatment Options for Myelodysplastic Syndromes

This program is supported by educational grants from Abbvie Inc., Geron Corporation, Gilead Sciences Inc., Karyopharm Therapeutics Inc. and Takeda Pharmaceuticals U.S.A., Inc.: Takeda Oncology Company. Provided by Clinical Care Options, LLC.

3:00 p.m. - 6:00 p.m. Eastern time
Atlanta Marriott Marquis
Atrium A

New science has driven innovative medical practice in the management of myelodysplastic syndromes (MDS) with hypomethylating agents (HMAs; including oral formulations), erythropoiesis-stimulating agents (ESAs), immunosuppressants, lenalidomide, and luspatercept. This symposium will focus on evolving therapeutic standards and emerging therapeutic options with expert faculty providing practical insights for disease and supportive care management of MDS. Using different case presentations, the experts will discuss key clinical questions, available supporting evidence, and challenges that affect therapeutic decisions as well as their individual treatment recommendations for each case. Throughout the symposium, learners will be able to vote on case scenarios and directly text questions to the panel for their consideration. Discussion topics will include:

• Risk stratification in MDS
• Managing anemia in very low–risk, low-risk, or intermediate-risk MDS
• Novel therapeutic approaches for lower-risk MDS
• Latest guidance on treating higher-risk MDS and managing relapsed/refractory MDS
• Future directions on key clinical trials

Chair:

Michael R. Savona , MD
Vanderbilt University School of Medicine; Ingram Cancer Center
Nashville,  TN

Speakers:

Jacqueline S. Garcia , MD
Medical Oncology
Boston,  MA

Amer M. Zeidan , MD
Yale University School of Medicine
East Haven,  CT

Clinical Care Options , Meetings Department
Email: meetings@clinicaloptions.com

Registration for In-Person Program

Addressing Clinical Challenges in T-Cell Lymphomas Through Biomarker-Driven Therapy

This program is supported by Supported by educational grants from Daiichi Sankyo, Inc., Kyowa Kirin, Seagen Inc. and Takeda Oncology. Provided by Clinical Care Options, LLC.

3:00 p.m. - 6:00 p.m. Eastern time
Atlanta Marriott Marquis
Marquis Ballroom BCD

This symposium will feature presentations and panel discussions with perspectives and recommendations from multiple experts. In addition, the expert panel will address audience questions, challenges, and cases identified in the “Live Case and Question Submission” that are sent directly to the faculty. At the live symposium, all attendees will be provided with a networked IML connector (or online polling capability), an all-in-one handheld device that enables learners to fully interact in case management voting. Of importance, the IML technology is preferred over “standard ARS,” as it adds the ability for learners to submit questions to the expert faculty by text message, thereby directly contributing to the content and outcome of the symposium. This symposium format will provide an interactive way to disseminate cutting-edge information and expert perspectives to learners, while also addressing educational gaps related to the translation of practice-changing data into clinical practice.

Chair:

Steven M. Horwitz , MD
Memorial Sloan Kettering Cancer Center
New York,  NY

Speakers:

Francine M. Foss , MD
Yale Cancer Center
New Haven,  CT

Barbara Pro , MD
Northwestern University
Chicago,  IL

Clinical Care Options , Meetings Department
Email: meetings@clinicaloptions.com

Registration for In-Person Program

Adopting MRD Assessment for Hematologic Malignancies in Real-World Settings: Technique, Role, and Utilization to Improve Patient Outcomes

This program is supported by Adaptive Biotechnologies

3:00 p.m. - 6:00 p.m. Eastern time
Hyatt Regency Atlanta
Centennial 2

The live portion of this curriculum will be presented as a 3-hour Friday Satellite Symposium (FSS) held prior to the ASH Annual Meeting. The live activity will feature a series of didactic presentations coupled with Medical Crossfire® from prominent experts in the field. To set the stage, a “Real World” interview with a community oncologist be used as a starting point to discuss the latest data for MRD monitoring and their implications for clinical practice.

Chair:

Jerry P. Radich , MD
Fred Hutchinson Cancer Research Center
Seattle,  WA

Speakers:

Irene M. Ghobrial , MD
Dana-Farber Cancer Institute
Boston,  MA

Lori Muffly , MD, MS
Stanford University School of Medicine
Stanford,  CA

Mark Roschewski , MD
National Cancer Institute, National Institutes of Health
Bethesda,  MD

Phil Talamo , Physicians' Education Resource, LLC
Email: ptalamo@GOTOPER.COM

Aligning the Evidence with the Patient to Individualize Treatment Considerations Along the CML Care Continuum

This program is supported by Physicians' Education Resource, LLC (PER)

3:00 p.m. - 6:00 p.m. Eastern time
VIRTUAL PROGRAM

This virtual live program is designed to update physicians on the issues important to the long-term safety of targeted treatments for management of CML, and new treatment options for the management of CML across lines of care. In addition, this program will offer physicians strategies for monitoring treatment response and making appropriate therapeutic choices across the disease course considering safety and patient-specific factors as part of the decision-making process. The symposium will also incorporate the patient voice through pre-recorded video clips capturing his/her experience to then bridge into a discussion on clinical decision-making. The symposium is designed to educate audiences in an innovative, engaging format and will include a mix of didactic lecture, case-studies, panel discussions, and Q&A. The program is designed to be fast-paced and highly interactive between faculty and audience. Case-studies and panel discussions will be used by the Chair to challenge faculty on their treatment decisions and to give the opportunity for the audience to reflect on best practices and their own clinical decisions for higher educational engagement.

Chair:

Jorge E. Cortes , MD
Georgia Cancer Center Augusta University
Augusta,  GA

Speakers:

Vivian G. Oehler , MD
Fred Hutchinson Cancer Research Ctr.
Seattle,  WA

Charles A. Schiffer , MD
Karmanos Cancer Institute at Wayne State University
Detroit,  MI

Phil Talamo , Physicians' Education Resource, LLC (PER)
Email: ptalamo@gotoper.com

Are You Up To Date on Non-CAR T-Cell Strategies for R/R Diffuse Large B-Cell Lymphoma?

This program is supported by Morphosys, Karyopharm, and Incyte

3:00 p.m. - 6:00 p.m. Eastern time
Omni Hotel at CNN Center
Grand Ballroom D1/D2

Outcomes for patients with diffuse large B-cell lymphoma (DLBCL) who relapse or are refractory (R/R) to first-line treatment are poor, especially those who are ineligible for progressed after stem cell transplantation. This activity will provide insights in the non-CAR T-cell treatment options available for this patient population in order to personalize and safely manage treatment and provide patients with the best care.

Chair:

Pier Luigi Zinzani , MD, PhD
Istituto Di Ematologia
Bologna,  Italy

Speakers:

Andre H. Goy , MD
John Theurer Cancer Center, Hackensack University Medical Center
Hackensack,  NJ

Kami J. Maddocks , MD
Ohio State University Hospital
Columbus,  OH

Kristen Holt Gresham , Medscape
Email: kholt@webmd.net

Registration for In-Person Program
Registration for Virtual Program

Asparaginase-Based Treatments in Young and Older Adults With Acute Lymphoblastic Leukemia: Leveraging the Pediatric Experience

This program is supported by educational grants from Jazz Pharmaceuticals, Servier Pharmaceuticals and Servier Oncology Global Medical and Patient Affairs. Provided by Clinical Care Options, LLC.

3:00 p.m. - 6:00 p.m. Eastern time
Atlanta Marriott Marquis
Atrium B

Dose-intensified, multiagent chemotherapy regimens, in which asparaginase plays a prominent role, have substantially improved outcomes for children and adolescents/young adults (AYAs) with acute lymphoblastic leukemia (ALL) in recent decades and are playing an increasing role in adult and older adult patients. This symposium, focused on the latest evidence to optimize the care of older patients with ALL using asparaginase, will provide practical expert guidance on current therapeutic strategies for monitoring/identifying clinical and subclinical asparaginase hypersensitivity and the latest recommendations for patient management. The symposium agenda will include didactic data presentations by experts with case challenges, moderated panel discussion, and audience interactivity with ample time for Q&A. Along with the experts, audience participants will explore key clinical questions, available evidence, and challenges that affect therapeutic decisions as well as receive personal expert treatment recommendations for each case. Throughout the symposium, learners will be able to vote on case scenarios and directly text questions to the panel for their consideration. Discussion topics will include:

• Overview of induction, consolidation, and maintenance treatment algorithms for ALL
• Strategies to increase completion of asparaginase-based treatment
• Leveraging the lessons and experience treating pediatric patients to optimize the care of AYA and adult patients with ALL

Chair:

Wendy Stock , MD
University of Chicago Medicine
Chicago,  IL

Speakers:

Emily Curran , MD
University of Cincinnati Cancer Institute
Cincinnati,  OH

Dan Douer , MD
Keck School of Medicine
Los Angeles,  CA

Scott C Howard , MD MSc
University of Tennessee Health Science Center
Memphis,  TN

Stephen Hunger , MD
Children’s Hospital of Philadelphia
Philadelphia,  PA

Clinical Care Options , Meetings Department
Email: meetings@clinicaloptions.com

Registration for In-Person Program

Assessing the Potential of Gene Therapies for Hemoglobinopathies – The Importance of Long-Term Data

This program is supported by Bluebird Bio, Inc.

3:00 p.m. - 6:00 p.m. Eastern time
Omni Hotel at CNN Center
Grand Ballroom E, M4/Grand Ballroom Level

Newly approved and emerging therapies for ß-thalassemia and sickle cell disease (SCD) have the potential to dramatically impact patient quality of life and health outcomes. This interactive educational program will address the long-term clinical evidence of gene therapy for hemoglobinopathies, discuss how gene therapy is implemented in clinical practice, and provide guidance on the management of patients as treatment paradigms evolve.

Chair:

Christine N. Duncan , MD
Boston Children's Hospital, Harvard Medical School
Boston,  MA

Speakers:

Jeanne Boudreaux , MD
Children's Healthcare of Atlanta, Emory University
Atlanta,  GA

Janet L. Kwiatkowski , MD, MSCE
Children's Hospital of Philadephia
Philadelphia,  PA

Kristen Holt Holt Gresham , Medscape
Email: kholt@webmd.net

Registration for In-Person Program
Registration for Virtual Program

Cold Agglutinin Disease: Shifting the Treatment Paradigm through Improved Understanding of the Complement System

This program is supported by Sanofi Genzyme

3:00 p.m. - 6:00 p.m. Eastern time
Hyatt Regency Atlanta
Centennial 4

This accredited satellite symposium will provide attendees with expert guidance and patient perspectives concerning the clinical impact of cold agglutinin disease (CAD) on patient quality of life, the role of the complement sytem in CAD, strategies for optimal identification and diagnosis, and implications for emerging treatments and management approaches.

The experts will engage in an open exchange of ideas and viewpoints fostered by a case-based agenda allowing them to review patient scenarios and perspectives, reflect on how they might handle particular cases, integrate relevant evidence into real-world practice, and compare their individualized patient care approaches with one another.

Unique to this symposium will be the participation of a patient living with cold agglutinin disease. The "patient-and-provider" interview will bring greater attention to the patient journey and further highlight burden of disease and quality of life, as well as considerations and concerns regarding management and therapeutic options.

Chair:

Alexander Roeth , MD
West German Tumor Center Essen
Essen,  Germany

Speakers:

Wilma Barcellini , MD
Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico
Milan,  Italy

Catherine M. Broome , MD
MedStar Georgetown University
Washington,  DC

Ilene C. Weitz , MD
Keck School of Medicine, University of Southern California
Los Angeles,  CA

Phil Talamo , Physicians' Education Resource, LLC (PER)
Email: ptalamo@GOTOPER.COM

Improving Outcomes and Quality of Life in ß-Thalassemia: Patient Perspectives and Expert Recommendations

This program is supported by Physicians' Education Resource, LLC (PER)

3:00 p.m. - 6:00 p.m. Eastern time
Hyatt Regency Atlanta
Centennial 1

This live program is designed to update physicians on the latest advancements in the clinical management of beta thalassemia, including strategies to manage transfusion dependence, transitioning care from pediatric to adult settings, and educating patients on new therapeutic options. In addition, the program will utilize pre-recorded patient video clips which highlight the burden of disease as well as the gaps in care. These conversations are designed to close gaps that currently exist within the continuum of beta-thalassemia care. The program is designed to provide real-word context to the faculty discussions and keep the patient focus top of mind. Panel discussions will be used by the Chair to challenge faculty on their treatment decisions and to give the opportunity for the audience to reflect on best practices and their own clinical decisions for higher educational engagement.

Chair:

Thomas D. Coates , MD
Children's Hospital of LA
Los Angeles,  CA

Speakers:

Antonis Kattamis , MD, PhD
'Agia Sophia' Children Hospital, First Department of Pediatrics, National and Kapodistrian University of Athens, Athens, Greece
Athens,  Greece

Ali T. Taher , MD,PhD,FRCP
American University of Beirut Medical Center
Beirut,  Lebanon

Dayna Kleinstein , Physicians' Education Resource® (PER®)
Email: dkleinstein@gotoper.com

The Evolving Landscape of Complement Inhibition Therapy: Implications for Hematology Practice

This program is supported by Alexion Pharmaceuticals, Inc.

3:00 p.m. - 6:00 p.m. Eastern time
Omni Hotel at CNN Center
Grand Ballroom A-C, M4/Grand Ballroom Level

Listen to faculty discuss key components of the complement pathway, its underlying pathophysiology and how it is different in atypical haemolytic uremic syndrome (aHUS), thrombotic microangiopathy (TMA), and paroxysmal nocturnal hemoglobinuria (PNH). Experts in each disease area will then present a patient case and provide insight on the management of these patients; will review key current and emerging clinical data; will identify important patient- and disease-related factors that aid in the personalization of care; will share experiences on how to manage adverse effects; how to effectively communicate treatment considerations with patients; and the integral role of the multidisciplinary team in managing these patients. There will be an opportunity to learn more from the faculty during a live Q&A session.

Chair:

Spero Cataland , MD
Ohio State University Medical Center
Columbus,  OH

Speakers:

Sonata Jodele , MD
Cincinnati Children’s Hospital Medical Center
Cincinnati,  OH

Srikanth Nagalla , MD,MS
Miami Cancer Institute
Miami,  FL

Kristen Holt Gresham , Medscape
Email: kholt@webmd.net

Registration for In-Person Program
Registration for Virtual Program

Thinking Outside of the Vial: Evaluating the Intricacies of Care for Patients with Iron Deficiency Anemia

This program is supported by Pharmacosmos Therapeutics, Inc.

3:00 p.m. - 6:00 p.m. Eastern time
Hyatt Regency Atlanta
International North/South

Iron deficiency anemia (IDA) continues to be a significant public health burden that can lead to a number of adverse health outcomes. Join our expert faculty for a satellite symposium, in coordination with the 2021 ASH Annual Meeting, as they discuss the intricacies of managing patients with iron-deficiency anemia. Take a deep dive into the practical implications of efficacy and safety data surrounding the IDA treatment landscape. Test your knowledge and skills against that of your colleagues in a quickfire polling segment. Then join the faculty for an extended Q&A session, allowing audience engagement with the entire panel. This will be a lively symposium filled with expert discussion and clinical pearls.

Chair:

David H. Henry , MD
University of Pennsylvania
Philadelphia,  PA

Speakers:

Myles Wolf , MD, MMsc
Duke University School of Medicine
Durham,  NC

Michelle P. Zeller , MD
McMaster University
Hamilton,  ON, Canada

Jae Eising , Medscape Education
Email: jeising@medscapelive.com

Registration for In-Person Program
Registration for Virtual Program

WHAT CLINICIANS WANT TO KNOW: Addressing Current Questions and Controversies in the Management of Multiple Myeloma (Part 3 of a 4-part CME/MOC-accredited Symposia Series)

This program is supported by Bristol-Myers Squibb Company, GlaxoSmithKline, Karyopharm Therapeutics, Oncopeptides and Sanofi Genzyme.

3:00 p.m. - 6:00 p.m. Eastern time
Omni Hotel at CNN Center
International Ballroom E-F, M2/International Ballroom Level

This CME/MOC program, part 3 of a 4-part series, will focus on the management of patients with multiple myeloma. Five investigators will serve as faculty, one of whom will moderate the event. Prior to the program, Research To Practice (RTP) will recruit 5 general medical oncologists and hematologists to help frame the program’s content and agenda. RTP will work with these individuals to identify specific challenging clinical situations or questions from their practice for which they would seek input from an investigator. These clinicians will then participate in a Working Group session during which their questions will be presented. The session will be video-recorded and RTP will select excerpts for presentation during the live meeting. The symposium agenda will be divided into 5 modules, each featuring the presentation and discussion of video excerpts from the Working Group and a faculty member-led presentation formally reviewing emerging research relevant to the issues and scenarios being presented. To make the event even more relevant, attendees will use iPads to participate in a survey related to the topics, questions and cases discussed. Polling results will be interspersed throughout each module to foster additional debate. The program will also be simulcast for attendees participating virtually.

Chair:

Robert Z. Orlowski
The University of Texas MD Anderson Cancer Center
Houston,  TX

Speakers:

Larry D. Anderson Jr. , MD, PhD
UT Southwestern Medical Center
Dallas,  TX

Morie A. Gertz , M.D.
Mayo Clinic
Rochester,  MN

Irene M. Ghobrial , MD
Dana-Farber Cancer Institute
Boston,  MA

Peter M. Voorhees , MD
Levine Cancer Center
Charlotte,  NC

Sylvia Eriksen , Research To Practice
Email: meetings@researchtopractice.com

Registration for In-Person Program
Registration for Virtual Program

A Class in Session: Understanding Current and Future Therapeutic Advances Across B-Cell Lymphomas

This program is supported by Atara Biotherapeutics, Inc., Bayer Healthcare Pharmaceuticals Inc., Beigene, Ltd., Epizyme, Genentech, Genmab US, Inc., Incyte Corporation, Karyopharm Therapeutics and Pharmacyclics LLC

7:00 p.m. - 10:00 p.m. Eastern time
Atlanta Marriott Marquis
Atrium B

This symposium will be a one-stop opportunity to catch up on rapidly changing clinical data on recently approved and investigational agents as well as combination regimens across multiple diverse lymphomas, including FL, MZL, MCL, DLBCL, and PTLD. A panel of experts will share their approach to therapeutic decisions for patients across B-cell lymphomas considering risk stratification and the current treatment landscape, while providing a look ahead at new data and promising agents that may change practice in the near future. This symposium will include numerous patient case challenges accompanied by treatment recommendations from each expert for each case. Presentations will review available clinical trial evidence and ongoing clinical trials on novel therapeutic approaches, including targeted therapies, immune therapies (eg, antibody–drug conjugates, bispecific antibodies, immune checkpoint inhibitors, and CAR T-cell therapies), epigenetic therapies, and new combination regimens across B-cell lymphomas. Throughout the symposium, those in the audience will have chances to interact with the experts through interactive case-based challenges, polling questions, and moderated question and answer sessions that include questions sent directly to the presenters from the audience by text message.

Chair:

Julie M. Vose , MD, MBA
University of Nebraska Medical Center- Fred and Pamela Buffett Cancer Center
Omaha,  NE

Speakers:

Brad S. Kahl , MD
Washington University School of Medicine in St. Louis
Saint Louis,  MO

John P. Leonard , MD
Weill Cornell Medicine and New York Presbyterian Hospital
New York,  NY

Clinical Care Options , Meetings Department
Email: meetings@clinicaloptions.com

Acquired Thrombotic Thrombocytopenic Purpura: Clinical Application of Precision Medicine and New Guidelines

This program is supported by an educational grant from Sanofi Genzyme. Provided by Clinical Care Options, LLC.

7:00 p.m. - 10:00 p.m. Eastern time
Atlanta Marriott Marquis
Atrium A

New science has driven innovative medical practice in the recognition and management of acquired thrombotic thrombocytopenic purpura (aTTP). This symposium will cover the continuum of care from disease diagnosis and risk stratification to practical guidance for therapeutic strategies in both initial and relapsed/refractory aTTP including new treatment options and review the latest research progress on emerging therapeutic approaches for this disease. During the symposium, program faculty will interact with the audience through the discussion of case examples and a moderated question and answer session and panel discussion. Discussion will include review of key clinical questions, available evidence, and challenges that affect therapeutic decisions as well as personal treatment recommendations from each panelist for the presented cases. Throughout the symposium, learners will be able to vote on case scenarios and text questions to the panel for their consideration. Discussion topics include:

• Diagnosis and initial management
• Management of relapsed/refractory disease
• Future directions and ongoing trials

Chair:

Ara Metjian , MD
University of Colorado Medicine
Aurora,  CO

Speakers:

Paul Coppo , MD, PhD
Sorbonne University
Paris,  France

Marshall Mazepa , MD
University of Minnesota
Minneapolis,  MN

Clinical Care Options , Meetings Department
Email: meetings@clinicaloptions.com

Bridging Clinical Gaps in B-Cell Lymphomas: Linking Novel Mechanisms to Advance New Treatment Strategies

This program is supported by Incyte

7:00 p.m. - 10:00 p.m. Eastern time
VIRTUAL PROGRAM

The live portion of this curriculum will be presented as a 3-hour Friday Satellite Symposium (FSS) held prior to the ASH Annual Meeting. The live activity will feature a series of didactic presentations coupled with case presentations from prominent experts in the field that will be used as a starting point to discuss the latest data across forms of NHL.

• The activity is designed to highlight and test participants on the most clinically relevant data in NHL, provide expert guidance on the interpretation of core concepts, and forecast the clinical impact of recent data sets.
• The faculty panel will convene to share their own practice preferences (“How I treat”), perspectives on the clinical trial data and share clinical pearls from their own practices.
• To further enhance the integration of recent data into practice, the program will feature an interactive question-and-answer session with faculty throughout the activity to emphasize areas of educational need, highlighting areas of debate, and illustrating the application of new data in defined clinical situations.

Chair:

Jason R. Westin , MD, MS, FACP
MD Anderson
Houston,  TX

Speaker:

Andre H. Goy , MD
John Theurer Cancer Center, Hackensack University Medical Center
Hackensack,  NJ

Phil Talamo , Physicians' Education Resource, LLC
Email: ptalamo@GOTOPER.COM

Caring for Patients With Hemophilia A in the Midst of a Therapeutic Revolution

This program is supported by educational grants from Genentech, a member of the Roche Group, Sanofi Genzyme and Takeda Pharmaceuticals U.S.A., Inc.: Takeda Oncology Company. Provided by Clinical Care Options, LLC.

7:00 p.m. - 10:00 p.m. Eastern time
Atlanta Marriott Marquis
Marquis Ballroom BCD

In this symposium, learners will be presented with an overview of current individualized therapeutic approaches for managing patients with hemophilia A and a look ahead at new data and promising agents that may soon affect practice. Renowned experts in hemophilia will discuss the evidence behind current best practices for patients with hemophilia A requiring prophylaxis, both in the presence and absence of inhibitors. The program will include interactive pertinent patient case challenges and discussions of considerations that affect therapeutic choices. Recent clinical trial data and key ongoing trials will be discussed, including emerging extended half-life clotting factors and tailoring therapy with pharmacokinetic (PK) monitoring, humanized bispecific antibody therapy, and novel therapeutic approaches with antithrombin inhibitors, anti-TFPI antibodies, and gene therapy. Learners will gain an understanding of how these agents will affect management strategies for patients with hemophilia A today and in the near future. Throughout the symposium, attendees will interact with experts through the interactive case polling questions and texting questions directly to the panel for their consideration.

Chair:

Miguel A. Escobar , MD
University of Texas Health Science Center
Houston,  TX

Speakers:

Mark T Reding , MD
University of Minnesota Medical Center
Minneapolis,  MN

Guy Young , MD
University of Southern California Keck School of Medicine
Los Angeles,  CA

Clinical Care Options , Meetings Department
Email: meetings@clinicaloptions.com

Cytopenic Myelofibrosis: What Is It and How Can We Treat It?

This program is supported by CTI BioPharma Corp.

7:00 p.m. - 10:00 p.m. Eastern time
Omni Hotel at CNN Center
Grand Ballroom A-C, M4/Grand Ballroom Level

Myelofibrosis (MF) is one of a group of heterogeneous hematopoietic disorders that constitute myeloproliferative neoplasms (MPNs). The severity of these disorders can range from mild to aggressive, and the diseases are associated with shortened survival and greatly compromised quality of life. Cytopenias in MF are common and often problematic and are the most common reason for interruption and/or dose reduction. Our expert panel will guide us in an interactive discussion on the unmet medical need for patients with cytopenic MF, the current treatment approaches and emerging therapies that can be used in cytopenic patients.

Our expert panel will guide us in an interactive discussion on the unmet medical need for patients with cytopenic MF, the current treatment approaches and emerging therapies that can be used in cytopenic patients.

Chair:

Ruben A. Mesa , MD, FACP
UT Health San Antonio Cancer Center
San Antonio,  TX

Speakers:

Raajit Rampal , MD, PhD
Memorial Sloan Kettering Cancer Institute
New York,  NY

Srdan Verstovsek , MD, PhD
M.D. Anderson Cancer Center
Houston,  TX

Kristen Holt Gresham , Medscape
Email: kholt@webmd.net

Healthcare Team Collaborative: Optimizing Treatment and Prevention of VTE in Patients with Hematologic Malignancies

This program is supported by Physicians' Education Resource, LLC (PER)

7:00 p.m. - 10:00 p.m. Eastern time
VIRTUAL PROGRAM

This symposium feature a multidisciplinary panel of oncologists who are well versed in the treatment of cancers that are associated with a high risk of VTE, and hematologists who are experts in VTE guidelines and treatment. It will feature a didactic overview of unmet need, likelihood of recurrence, and coordination of care between the different disciplines. This will be followed by several detailed case presentations to assist in the application of key strategies into defined patient care scenarios.

Chair:

Alok A Khorana , MD
Cleveland Clinic Foundation
Cleveland,  OH

Speakers:

Dana E. Angelini , MD
Cleveland Clinic Foundation
Avon Lake,  OH

Marc Carrier
University of Ottawa/The Ottawa Hospital
Ottawa,  ON, Canada

Dayna Kleinstein , Physicians' Education Resource® (PER®)
Email: dkleinstein@gotoper.com

Overcoming Cancer-Related Anemia With Intravenous Iron: Hematologist/Oncologist Approaches For Optimizing Clinical Outcomes and Improving Patient Quality Of Life

This program is supported by Creative Educational Concepts

7:00 p.m. - 10:00 p.m. Eastern time
Hyatt Regency Atlanta
International North/South

Activity attendees will be given the opportunity to interact with expert faculty across all clinically relevant aspects of cancer-related anemia (CRA) management, including chemotherapy-induced anemia (CIA). The session will begin with a review of iron metabolism and absorption, including the distinctions between absolute and functional iron deficiency, and the impact of those distinctions on treatment decisions. An appraisal of the etiology and foundational pathophysiology of CRA will follow, with a central emphasis on the role of hepcidin and functional iron deficiency (FID) in a hyperinflammatory disease state like cancer, and how those processes should lead to preferential use of intravenous (IV) iron versus oral iron in patients with cancer. Completed and ongoing clinical trials of IV iron for CRA will be examined, and next generation formulations with nanocolloidal drug design will be highlighted, especially their improved safety profiles. Finally, using real-world patient cases, hematology/oncology experts will share insights on how and why IV iron possesses the capacity to revolutionize treatment of CRA and CIA.

Chair:

George M. Rodgers , MD, PhD
Univ. of Utah Medical Center
Salt Lake City,  UT

Speakers:

Michael Auerbach , MD, FACP
Auerbach Hematology and Oncology
Baltimore,  MD

Thomas G. Deloughery , MD
Oregon Health and Science Univ.
Portland,  OR

John Glaspy , MD, MPH
UCLA School of Medicine
Los Angeles, 

Patricia A. Locantore-Ford , MD
University of Pennsylvania, Penn Medicine
Philadelphia,  PA

Jessica Hall , Creative Educational Concepts
Email: jhall@ceconcepts.com

The Tonight Show With Expert Hematologists: Let’s Talk About PNH

This program is supported by Apellis Pharmaceuticals, Inc.

7:00 p.m. - 10:00 p.m. Eastern time
Omni Hotel at CNN Center
Grand Ballroom E, M4/Grand Ballroom Level

This interactive, talk show-themed, 90-minute live symposium will feature a panel of experts who will discuss key concepts and provide guidance related to the diagnosis and management of paroxysmal nocturnal hemoglobinuria (PNH). A patient video vignette will be included to showcase the patient perspective along with interactive case challenges provided by faculty to discuss the best approaches for effective treatment and management decisions. Near the conclusion of the event, expert faculty will identify key clinical pearls for PNH, followed by a robust Q&A session. Attendees will be also be able to engage in pre-/post assessment questions to test their knowledge and real-time polling during the discussions.

Chair:

Ilene C. Weitz
Keck-USC School of Medicine
Los Angeles,  CA

Speakers:

Catherine M Broome
MedStar Georgetown University
Washington,  DC

Carlos M. de Castro , MD
Duke University School of Medicine
Durham,  NC

Kristen Holt Gresham , Medscape
Email: kholt@webmd.net

WHAT CLINICIANS WANT TO KNOW: Addressing Current Questions and Controversies in the Management of Acute Myeloid Leukemiaand Myelodysplastic Syndromes (Part 4 of a 4-part CME/MOC-accredited Symposia Series)

This program is supported by Jazz Pharmaceuticals Inc and Genentech, a member of the Roche Group.

7:00 p.m. - 10:00 p.m. Eastern time
Omni Hotel at CNN Center
International Ballroom E-F, M2/International Ballroom Level

This CME/MOC program, part 4 of a 4-part series, will focus on the management of Acute Myeloid Leukemia and Myelodysplastic Syndromes. Five investigators will serve as faculty, one of whom will moderate the event. Prior to the program, Research To Practice (RTP) will recruit 5 general medical oncologists and hematologists to help frame the program’s content and agenda. RTP will work with these individuals to identify challenging clinical situations or questions from their practice for which they would seek input from an investigator. These clinicians will then participate in a Working Group session during which their questions will be presented. The session will be video-recorded and RTP will select excerpts for presentation during the live meeting. The symposium agenda will be divided into 5 modules, each featuring the presentation and discussion of video excerpts from the Working Group and a faculty member-led presentation formally reviewing emerging research relevant to the issues and scenarios being presented. To make the event even more relevant, attendees will use iPads to participate in a survey related to the topics, questions and cases discussed. Polling results will be interspersed throughout each module to foster additional debate. The program will also simulcast for virtual participants.

Speakers:

Guillermo Garcia-Manero , MD
University of Texas
Houston,  TX

Alice S. Mims , MD
The Ohio State University
Columbus,  OH

Richard M. Stone , MD
Dana-Farber Cancer Institute
Boston,  MA

Andrew H. Wei , MBBS,PhD
The Alfred Hospital
Melbourne,  VIC, Australia

Sylvia Eriksen , Research To Practice
Email: meetings@researchtopractice.com